Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | WDR5 | P61964 | 4/20 | 0.51 |
| ▸ | MYC | P01106 | 1/20 | 0.51 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | EDNRB | P24530 | 1/20 | 0.48 |
| ▸ | EDNRA | P25101 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL25341724 | 0.98 | SMN1; SMN2 (0.58) | SMN1; SMN2TSHRGLAPKMGAA | |
| Hydrochloric Acid SCHEMBL27865616 | 0.98 | SMN1; SMN2 (0.58) | SMN1; SMN2TSHRGLAPKMGAA | |
| SCHEMBL31556387 | 0.85 | PKM (0.53) | SMN1; SMN2TSHRGLAPKMGAA | |
| SCHEMBL16005133 | 0.85 | PKM (0.53) | SMN1; SMN2TSHRGLAPKMGAA | |
| SCHEMBL1790129 | 0.83 | SMN1; SMN2 (0.65) | SMN1; SMN2TSHRGLAPKMGAA | |
| SCHEMBL30514814 | 0.83 | SMN1; SMN2 (0.65) | SMN1; SMN2TSHRGLAPKMGAA | |
| SCHEMBL7421633 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2TSHRGLAPKMGAA | |
| SCHEMBL29902299 | 0.81 | SMN1; SMN2 (0.64) | SMN1; SMN2TSHRGLAPKMGAA | |
| SCHEMBL47015 | 0.81 | SMN1; SMN2 (0.64) | SMN1; SMN2TSHRGLAPKMGAA | |
| SCHEMBL27584635 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2TSHRGLAPKMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099404-A1 | SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | QUBIT PHARMACEUTICALS (FR) | 2026-05-15 | — | — | WO | disclosed |
| EP-4741375-A1 | SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Qubit Pharmaceuticals (FR) | 2026-05-13 | — | — | EP | disclosed |
| EP-4729515-A1 | NEW ACYLSULFONAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Qubit Pharmaceuticals (FR) | 2026-04-22 | — | — | EP | disclosed |
| EP-4680226-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | Olema Pharmaceuticals, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260015327-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS INC (US) | 2026-01-15 | — | — | US | disclosed |
| WO-2025201504-A1 | KAT6 INHIBITORS | BEIGENE (SUZHOU) CO., LTD. (CN) | 2025-10-02 | — | — | WO | disclosed |
| US-20250304535-A1 | KAT6 Inhibitors | BEIGENE SWITZERLAND GMBH (CH) | 2025-10-02 | — | — | US | disclosed |
| US-12428379-B2 | Acylsulfonamide KAT6A inhibitors | OLEMA PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250136553-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250122152-A1 | KAT6 Inhibitors | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-17 | — | — | US | disclosed |
| WO-2011094953-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| EP-1812388-B1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS EHF (IS) | 2011-02-23 | — | — | EP | disclosed |
| US-20090291948-A1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS EHF (IS) | 2009-11-26 | — | — | US | disclosed |
| US-7598397-B2 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | DECODE GENETICS EHF (IS) | 2009-10-06 | — | — | US | disclosed |
| EP-1812388-A1 | SULFONAMIDE PERT-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | Decode Genetics (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006044000-A1 | SULFONAMIDE PERT-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060079520-A1 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | SAGA INVESTMENTS LLC | 2006-04-13 | — | — | US | disclosed |
| US-6242493-B1 | PROSTAGLANDIN INHIBITORS; ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2001-06-05 | — | — | US | disclosed |
| EP-1071648-A2 | CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck Frosst Canada & Co. (CA) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999047497-A2 | CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK FROSST CANADA & CO. (CA) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136553-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | SMN1; SMN2 1852/4885TSHR 3801/4885GLA 1691/4885 |
| US-20250304535-A1 | KAT6 Inhibitors | KAT6A, KAT6B, KAT2A | SMN1; SMN2 1106/4885TSHR 2862/4885GLA 2741/4885 |
| US-12428379-B2 | Acylsulfonamide KAT6A inhibitors | KAT6A, KAT2A, KAT6B | SMN1; SMN2 1852/4885TSHR 3801/4885GLA 1691/4885 |
| US-20060079520-A1 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | PTGIS, PTGIR, PTGS2 | SMN1; SMN2 2906/4885TSHR 3907/4885GLA 371/4885 |
| US-20260015327-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | SMN1; SMN2 3098/4885TSHR 1910/4885GLA 1993/4885 |
| US-20090291948-A1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | PTGIS, PTGIR, PTGS2 | SMN1; SMN2 2906/4885TSHR 3907/4885GLA 371/4885 |
| US-20250122152-A1 | KAT6 Inhibitors | KAT6A, KAT6B, KAT7 | SMN1; SMN2 1499/4885TSHR 3646/4885GLA 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.